ProQR Therapeutics NV expected to post a loss of 9 cents a share - Earnings Preview

ProQR Therapeutics NV

07/03/2025 12:39

ProQR Therapeutics NV PRQR.OQ PRQR.O is expected to show a fall in quarterly revenue when it reports  results on March 10 (estimated) for the period ending December 31 2024

The Leiden Zuid-holland-based  company is expected to report a 5.2% decrease in revenue to €5.894 million from €6.22 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for ProQR Therapeutics NV is for a loss of 9 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for ProQR Therapeutics NV is $10.00​, above​ its last closing price of $1.94. ​​​

Previous quarterly performance (using preferred earnings measure in euros). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.10
-0.11
-0.10
Beat
5.2
Jun. 30 2024
-0.11
-0.12
-0.03
Beat
75.9
Mar. 31 2024
-0.12
-0.11
-0.09
Beat
17.8​
Dec. 31 2023
-0.10
0.01
-0.07
Missed
-745.2
​​Sep. 30 2023
-0.10
-0.09
-0.07
Beat
17.8
Jun. 30 2023
-0.11
-0.11
-0.10
Beat
10​
Mar. 31 2023
-0.09
-0.12
-0.11
Beat
6.5
Dec. 31 2022
-0.17
-0.18
-0.16
Beat
10.4

This summary was machine generated March 7 at 12:39 GMT.  All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)